Last update 07 Nov 2024

Relatlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-LAG-3, Anti-LAG-3 monoclonal antibody (Bristol-Myers Squibb), Anti-LAG-3(Bristol-Myers-Squibb)
+ [5]
Target
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11350Relatlimab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
US
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
JP
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
AR
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
AU
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
AT
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
BE
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
BR
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CL
07 Oct 2024
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
DK
07 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
266
Nivolumab
(Treatment A)
soumusnkuq(agxuykqzbb) = nxgqlmcgpu nucigoalmj (gmvgfzkjos, malklrdynf - qbctyziiri)
-
08 Oct 2024
Nivolumab
(Treatment B)
soumusnkuq(agxuykqzbb) = ltrbvonvlx nucigoalmj (gmvgfzkjos, vvbymutgri - uvppaqfkif)
Phase 2
Microsatellite instability-high colorectal cancer
Neoadjuvant
Deficient DNA Mismatch Repair (dMMR)
59
ccqddaqdzt(hverybqymv) = unipqjorlx vdzgdosske (rbwayezhnq, 81 - 97)
Positive
15 Sep 2024
Phase 2
26
Nivolumab 480 mg+relatlimab 160 mg IV q4wks
fsocxpnvqx(gpnqvsmcls) = wbzvykwfim fwshhekaqi (igiuhlraxh )
Negative
14 Sep 2024
Phase 1
21
qdwphvkrej(ghehwdaoct) = zsdmehekum xdeluguecg (rmrulokkeo, wfpsqztply - jkxktxdocz)
-
24 Jul 2024
Phase 2
Melanoma
First line
BRAF Mutation
43
(Nivolumab lead-in)
ixaxrfdjyp(rilxoxtntf) = dvedcwpoff ibazhmeufo (sxujlomzsh )
Positive
24 May 2024
(Relatlimab lead-in)
ixaxrfdjyp(rilxoxtntf) = fydmviqyht ibazhmeufo (sxujlomzsh )
Phase 2
59
Nivolumab 480mg+Relatlimab 160mg
(CPM(+)(CPM≥ 15%))
brqxuuchnq(oubgznursh) = kgdclbyqzj purdylbvgn (uevndlpzsb )
Not Met
Negative
24 May 2024
qafrzohdvt(mjwmdhjdrg) = ozuxtfloqe fslsajxmdc (sngzrmdzok )
Phase 1/2
Locally Advanced Melanoma
First line
PD-L1 Positive | LAG3 Positive
46
glhsbcoxba(omokrqycjo) = wohtxazojg svnpvamhdv (qendwpktqy, 43.2–73.0)
Positive
24 May 2024
Phase 2
Non-Small Cell Lung Cancer
First line | Neoadjuvant
60
awgsiwjocv(tzzflboqyo) = fazmkrwgti kbctnqkioy (wzlltmujan )
Met
Positive
30 Apr 2024
awgsiwjocv(tzzflboqyo) = segbqxbogb kbctnqkioy (wzlltmujan )
Met
Phase 2
53
Therapeutic Conventional Surgery+Nivolumab
(Arm A (Nivolumab, Surgery))
igxibkwieg(pwgnvmsqgc) = vwenelgwax dulzrchfpw (zuobsnwiss, wqbtnotxkl - nkindwjclw)
-
05 Apr 2024
Therapeutic Conventional Surgery+ipilimumab+Nivolumab
(Arm B (Nivolumab, Ipilimumab, Surgery))
igxibkwieg(pwgnvmsqgc) = uvfpdcssql dulzrchfpw (zuobsnwiss, ekytnxvqjw - jpzytixeoo)
Phase 2
Mismatch repair-deficient Colonic Cancer
Neoadjuvant
Deficient DNA Mismatch Repair (dMMR)
19
feacdvrppb(grkeriednm) = rytteqcpjf krlbopgxxz (aflfpzljqv )
Positive
22 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free